Domain Therapeutics announces first patient dosed with DT-9081 in phase I clinical study in patients with advanced, recurrent or metastatic solid tumors:.
Domain Therapeutics strengthens Scientific Advisory Board with appointment of immuno-oncology experts streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Domain Therapeutics to progress into clinical trials with its EP4R antagonist DT-9081 in solid tumors Clinical trial applications accepted in France and.
FineHeart S.A, a preclinical medical device company that has developed the ICOMS FLOWMAKER, a fully Implantable Cardiac Output Management System designed to address the unmet need of patients suffering